

**Original Article, Endocrine.**

**Factors Affecting Ablation outcome in Low and Intermediate Risk Patients with Differentiated Thyroid Cancer.**

**Mohamadien, N<sup>1</sup>. Eloteify, L<sup>1</sup> Abdelnaim, A<sup>1</sup>. Diab, W<sup>1</sup>.**

*<sup>1</sup>Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Assiut University, Egypt.*

**ABSTRACT:**

**Aim:** To evaluate factors affecting ablation outcome in low- and intermediate-risk patients with differentiated thyroid cancer (DTC) as classified by the American Thyroid Association (ATA). **Methods:** Patients with pathologically proven ATA low- or intermediate-risk-DTC were retrospectively recruited. Those with incomplete tumor-resection or distant metastases were excluded. Demographic and clinical data were collected from the patient's medical records. Prior to receiving I-131 ablation-therapy, each patient underwent a post-operative Tc<sup>99m</sup>-thyroid scan, baseline neck ultrasonography, baseline TG level (BTG), and anti-TG antibodies (TG-Abs). Patients received variable doses of I131

ablation, post-therapy I-131 whole body scan (WBS) was then performed. Six months later, laboratory testing, neck-ultrasound and WBS were conducted to evaluate the ablation outcome. A successful ablation outcome is defined as undetectable stimulated thyroglobulin with negative TG-Abs, free neck-ultrasound, and negative I-131-WBS. **Results:** Two hundred and fifty patients, 128 low-and 122 intermediate-risk, were included. The successful ablation rate was 62.5% in low-risk, compared to 59% in intermediate-risk group. Patients with negative <sup>99m</sup>Tc-thyroid scans and absent thyroid-capsule infiltration in the low-risk group have significantly higher successful-ablation rates (76.7% vs. 55.3 %, p:0.01 and 66.6 vs

62.5 %, p:0.03). In the intermediate-risk group, the successful-ablation rate in cases with low BTG was significantly higher than those with high BTG (67.7 % vs. 50%, P:0.04). Regression analysis revealed that negative thyroid scan and

**Conclusion:** In ATA-low-risk DTC patients, an intact thyroid capsule, and a negative thyroid scan were linked to a significantly higher successful-ablation outcome. Additionally, a negative thyroid scan and lower BTG were the significant

lower BTG are the significant predictor factors in low-risk patients (P: 0.03 and 0.04, respectively), while in intermediate-risk group, BTG was the only significant predictor factor (P: 0.007).

predictor factors for successful-ablation outcome. BTG was the only significant predictive factor in the intermediate-risk group, and it was linked to a higher successful-ablation rate.

**Keywords:** DTC, Extra thyroidal extension, Ablation outcome, Basal TG, radioactive iodine dose.

---

**Corresponding author:** Nsreen Mohamadien **E-mail:** [nsreen@aun.edu.eg](mailto:nsreen@aun.edu.eg)

## INTRODUCTION:

Differentiated thyroid carcinoma (DTC) includes papillary thyroid carcinoma which is the most common thyroid neoplasm (80% - 90%) followed by the follicular carcinoma (10% - 40%)<sup>(1, 2)</sup>. DTC, has a favorable prognosis with a 5- and 10-year survival rates of 97% and

93%, respectively<sup>(3)</sup>. The primary treatment strategy for thyroid carcinoma is surgery, followed by radioactive iodine therapy (RAIT), which can destroy any remnant thyroid tissue. Additional therapies include chemotherapy, radiation therapy, and targeted therapy. A successful

first-time radioactive iodine ablation therapy may result in lower costs and an improvement in quality of life at the same time. However, not all patients benefit from the first RAIT. Proper knowledge about factors associated with successful ablation, each patient can get the best possible care by altering treatment and follow-up schedules for individual patients according to risk factors. Risk-modulated therapy aims to reduce radiation damage while preserving success rates <sup>(4)</sup>.

DTC risk classification utilizing several staging methods based on a combination of the main tumor's size, specific histology, extra thyroidal dissemination, and age at diagnosis. It predicts the likelihood of local recurrence, developing metastases, and mortality in patients with

## **PATIENTS and METHODS:**

After the Institutional Review Board approved this retrospective study (IRB.no: 04-2023300264), we reviewed files of thyroid cancer patients presented to the nuclear medicine unit at Assiut University Hospital during the period from January 2015 to December 2021. Two hundred and

DTC <sup>(5)</sup>. Several studies evaluated the prognostic factors in DTC patients<sup>(6, 7)</sup>, **Amin et al.** concluded that proper ablation dose of RAIT and absence of distant metastasis are the significant predictors for excellent outcome in DTC patients<sup>(8)</sup>. **Husseini** found that stimulated BTG level is clinically essential and had a strong predictive value for successful ablation; consequently, increased pre-ablation TG could potentially be incorporated in the decision making for <sup>131</sup>I dosage and for prediction of ablation outcome<sup>(6)</sup>.

This study aimed to investigate different factors impacting the ablation outcome in low- and intermediate-risk DTC patients, according to the American Thyroid Association 2015 (ATA)<sup>(9)</sup>.

fifty patients with pathologically verified ATA low- and intermediate-risk DTC were enrolled. The 2015 ATA thyroid cancer recommendation is followed when determining the patient risk, either low or intermediate <sup>(9)</sup>. **Criteria of ATA low risk** <sup>(9)</sup>: Well differentiated thyroid carcinoma

with No local or distant metastases, resection of all macroscopic tumors, no loco-regional tumor invasion, no aggressive histology (columnar cell carcinoma, tall cell, or hobnail variant), no RAI-avid metastatic foci outside the thyroid bed on the first post-therapy I-131 WBS, no vascular invasion, clinical N0 or

<5 pathologic N1 micro metastases (<0.2cm in its largest dimension), encapsulated follicular variant of papillary thyroid cancer, intra thyroidal, well differentiated follicular thyroid cancer with capsular invasion and no or minimal vascular invasion (<4foci) and uni focal or multifocal papillary micro carcinoma.

#### **Criteria of ATA intermediate risk:**

Microscopic invasion of tumor into the peri-thyroidal soft tissues, radioactive iodine avid metastatic foci in the neck on the first post-therapy WBS, aggressive histology, papillary thyroid carcinoma with vascular invasion, clinical N1 or >5 pathologic N1 with all involved LNs <3cm in its largest dimension and multifocal papillary micro carcinoma with ETE.

All patients who underwent a total or nearly total thyroidectomy, along with or without regional lymph node dissection, were included in this study. Patients with incomplete tumor resection, distant metastases or incomplete data in the medical records were excluded. All data about age, gender, family history of thyroid cancer, thyroid stimulating

hormone (TSH) level, baseline serum TG level (BTG), thyroglobulin antibodies (TG-Abs), neck ultrasound (N-US), lympho-vascular invasion (LVI), focality of the tumor (uni focal or multifocal), type of surgery, Tc-99m thyroid scan and uptake value, dose of RAIT, and the time between diagnosis and I131 ablation therapy, diagnostic I-131 whole body scan (Dx WBS) and post-therapy whole body scan as well as results of follow up laboratory and radiological data were collected. Furthermore, the Tumor node and Metastasis (TNM) staging system was recorded for each individual patient. Patients were categorized into two subgroups according to their BTG level, group I had BTG <5 ng/ml, and Group II had BTG >5. Also, as regards RAIT dose,

patients were grouped into those who received a low dose of 30 mCi of I131 or those who received a high dose of I131 (80

mCi or more). All collected data were tabulated and statistically analyzed.

### **Follow-up and assessment of the ablation outcome.**

Patients' follow-up was obtained six months after therapy based on physical examination as well as laboratory and radiological evaluation, including serum levels of TSH, stimulated serum TG, TG-Abs, N-US, and diagnostic I131 WBS, to evaluate the ablation outcome. According to the 2015 ATA guidelines <sup>(9)</sup>, ablation outcome was divided into two categories.

**1- Successful ablation:** Is defined as undetectable stimulated serum TG (< 1 ng/mL), negative TG-Abs, free N-US (neither detectable pathological cervical LNs nor thyroid tissue), absence of RAI-131 uptake at the thyroid bed region or elsewhere in the scanned body at Dx WBS.

### **2- Unsuccessful ablation:**

. Indeterminate response: defined as a non-specific imaging result, faint thyroid bed uptake at the diagnostic I-131 scan, detectable stimulated TG, but < 10 ng/mL, detectable non-stimulated TG, but >1 ng/mL, and TG-Abs are either constant or decreasing without evidence of structural disease. Biochemical incomplete response: negative imaging results with stimulated TG > 10 ng/mL or non-stimulated TG > 1 ng/mL or rising serum TG-Abs. Structural incomplete response: persistent or newly identified structural disease in the thyroid bed in diagnostic I131 WBS, N-US or in cross-sectional imaging modalities with or without elevated TG.

### **Statistical tests:**

The data analysis software utilized was SPSS 26.0. Frequencies and percentages were used to express qualitative data, while mean  $\pm$  SD was used to summarize quantitative data. The

Chi-square test was employed to compare qualitative variables. To compare medians, we utilized the Mann-Whitney-U test. The study employed univariate and multivariate

regression analyses to identify the significant predictor factors associated with a successful outcome. Receiver operating characteristic (ROC) analysis with areas under the curve

(AUCs) was conducted to determine the best BTG and thyroid uptake cutoff values concerning the outcome. When the P-value was less than 0.05, it was deemed significant.

## RESULTS:

We recruited 250 patients (43 males and 207 females) aged 14 to 70 years, with a mean age of  $38.9 \pm 11.6$  years, out of them 178 patients aged  $\leq 45$  years. Only eight patients possessed a positive family history of thyroid cancer.

One hundred thirty-five patients underwent total or near total thyroidectomy without lymph node dissection, and the remaining 115 patients underwent thyroidectomy with lymph node dissection (67/115 patients had positive nodal metastasis). Regarding histopathological types, papillary carcinoma accounted for 94.8% of cases, while follicular carcinoma comprised the remaining 5.2%. One hundred twenty-eight patients have low risk compared to

122 with intermediate risk (**Table 1 and 2**). A successful ablation rate was 62.5 % in the low-risk group compared to 59 % for the intermediate-risk group (P:0.5). 48/128 patients with low-risk had unsuccessful ablation (22 cases had an incomplete response regarding structure, 8 had an incomplete response regarding biochemistry, and the remaining 18 cases had an indeterminate response) compared to 50/122 of those with intermediate-risk (12 had an incomplete response regarding structure, 14 had an incomplete response regarding biochemistry, and the remaining 24 cases had an indeterminate response) (**Table 3**). **Figures 1 and 2** represent successful and unsuccessful ablation outcomes, respectively.

**Table 1:** clinical and laboratory characteristics in patients with differentiated thyroid cancer in respect to their response to RAIT.

	Low Risk			Intermediate Risk		
	Successful	Unsuccessful	P	Successful	Unsuccessful	P
<b>Age:</b>						
• ≤45	55 (64 %)	31 (36%)	0.6	53 (57.6%)	39 (42.4%)	0.5
• >45	25(59.5%)	17 (40.5%)		19 (63.3%)	11 (36.7%)	
<b>Sex:</b>						
• Male	9 (64.3%)	5 (35.7%)	0.8	14 (48.3%)	15 (51.7%)	0.1
• Female	71(62.3%)	43 (37.7%)		58 (62.4%)	35 (37.6%)	
<b>Family history</b>						
• Positive	2 (66.7%)	1 (33.3%)	0.8	1 (20%)	4 (80 %)	0.07
• Negative	78(62.4%)	47 (37.6 %)		71 (60.7%)	46 (39.3%)	
<b>Thyroid scan:</b>						
• Negative	33(76.7%)	10 (23.3%)	<b>0.01</b>	37 (63.8%)	21 (36.2%)	0.3
• Positive	47(55.3%)	38 (44.7%)		35 (54.7%)	29 (45.3%)	
<b>BTG group:</b>						
• <5 ng/ml	38(64.4%)	21 (35.6%)	0.6	42 (67.7%)	20 (32.3%)	<b>0.04</b>
• >5 ng/ml	42(60.8%)	27 (39.2%)		30 (50 %)	30 (50 %)	
<b>Anti TG:</b>						
• Negative	58(%59.8)	39 (40.2%)	0.5	51 (60.7%)	33 (39.3 %)	0.6
• Positive	19(70.4%)	8 (29.6%)		19 (57.6%)	14 (42.4 %)	
• Border line	3 (75%)	1 (25%)		2 (40%)	3 (60 %)	
<b>Baseline neck US:</b>						
• Free	38(61.3%)	24 (38.7%)	0.7	33 (63.5 %)	19 (36.5%)	0.3
• Residual ± LNs	42(63.6%)	24 (36.7%)		39 (55.7 %)	31 (44.3%)	


**Table 2: Pathological characteristics and RAIT in patients with differentiated thyroid cancer in respect to their response to RAIT.**

	Low Risk			Intermediate Risk		
	Successful	Unsuccessful	P	Successful	Unsuccessful	P
<b>Surgery:</b>						
• Total thyroidectomy	56(60.9%)	36 (39.1%)	0.5	26(60.5%)	17 (39.5%)	0.8
• Total thyroidectomy +LN dissection	24(66.7%)	12 (33.3%)		46(58.2%)	33 (41.8%)	
<b>Pathology:</b>						
• Papillary	75 (62%)	46 (38%)	0.6	68(58.6%)	48 (41.4%)	0.6
• Follicular	5 (71.4%)	2 (28.6%)		4 (66.7%)	2 (33.3%)	
<b>N-stage:</b>						
• Nx	56(60.9%)	36 (39.1%)	0.7	26(60.5%)	17 (39.5%)	0.9
• N0	23(67.6%)	11 (32.4%)		8 (57.1%)	6 (42.9%)	
• N1	1 (50%)	1 (50%)		38(58.5%)	27 (41.5%)	
<b>Thyroid capsule infiltration:</b>						
• Not reported			<b>0.03*</b>			0.7
• Present	2 (22.2%)	7 (77.8%)		9 (69.2%)	4 (30.8%)	
• Absent	15(62.5%)	9 (37.5%)		32(58.2%)	23 (41.8%)	
	63(66.3%)	32 (33.7%)		31(57.4%)	23 (42.6%)	
<b>Focality:</b>						
• Uni focal	59(65.6%)	31 (34.4%)	0.2	27(61.4%)	17 (38.6%)	0.9
• Multifocal	20(58.8%)	14 (41.2%)		40 (58%)	29 (42%)	
• Not reported	1 (25%)	3 (75%)		5 (55.6%)	4 (44.4%)	
<b>Lympho vascular invasion:</b>						
• Absent			--			0.1
• Present	80(62.5%)	48 (37.5%)		46(63.9%)	26 (36.1%)	
	--			26 (52%)	24 (48%)	
<b>interval from surgery to initial RAI dose:</b>						
• <3 month	67(60.9%)	43 (39.1%)	0.3	56(55.4%)	45 (44.6%)	0.07
• >3 month	13(72.2%)	5 (27.8%)		16(76.2%)	5 (23.8%)	
<b>Dose of I-131:</b>						
• Low	40(66.7%)	20 (33.3%)	0.3	14 (56%)	11 (44%)	0.7
• High	40(58.8%)	28 (41.2%)		58(59.8%)	39 (40.2%)	




**Table 3: The overall ablation outcome rates.**

Final outcome		Total sample	Low risk	Intermediate risk
		No. (10)=250	No. 128	No. 122
Unsuccessful	Excellent response	152 (60.8 %)	80 (62.5%)	72 (59%)
	Biochemical incomplete response	22 (8.8 %)	8 (6.3 %)	14 (11.5%)
	Structural incomplete response	34 (13.6)	22 (17.2 %)	12 (9.8%)
	Indeterminate response	42 (16.8 %)	18 (14.1 %)	24 (19.7%)



**Figure (1):** A 48-yr-old female patient with ATA intermediate-risk papillary thyroid cancer underwent total thyroidectomy. Basal TSH=75.32 uIU/ml, BTG= 38.3ng/ml, TG-Abs was positive, and free N-US. (A): Tc99m-thyroid scan shows no residual functioning thyroid tissue, (B): post-therapy WBS, and (C) SPECT/CT images after receiving a RAI dose of 120 mCi, revealed residual active thyroid tissue at the right thyroid bed region. Six months later, TSH=59 uIU/ml, TG=0.04 ng/ml, TG- Ab was negative, and N-US was free, (D) Diagnostic I131 WBS and (E) the corresponding SPECT/CT images show no evidence of functioning iodine avid residual thyroid tissue denoting successful ablation.



**Figure (2)** A 56-yrs-old female patient with ATA-low risk papillary thyroid carcinoma, basal investigation after surgery was TSH >150, TG= 0.25 ng/ml, Anti-TG Abs =787.87 (positive), and N-US was free. (A) Tc-99m thyroid scan showing no residual functioning thyroid tissue. (B) Post-therapy I WBS after receiving 30 mCi of RAI shows residual thyroid tissue (C) SPECT/CT images of the post-therapy I 131WBS show that uptake corresponded to residual thyroid tissue at the left thyroid bed, follow-up after sixth month, TSH was 150, TG 0.04, TG-Abs 573 and N-US was free, image (D)Diagnostic I131 WBS revealed focal active tracer uptake at the neck corresponding to residual active thyroid tissue at the SPECT/CT images (E) denoting **unsuccessful ablation**.

Based on ATA risk stratifications, gender, type of surgery, LN stage, lymphovascular invasion(LVI), capsule infiltration, focality, thyroid scan, and the first ablation dose of RAIT were significantly different between the two risk groups (p:0.007, <0.01, <0.01, <0.01, <0.01, <0.01, 0.02, and <0.01, respectively) (**Table 4 and 5**). However, the age group, family history, pathologic

variant, N-US, BTG, TG-Abs, and the interval between surgery and RAIT dose were insignificantly different between the two risk groups (p:0.1, 0.4, 0.7, 0.3, 0.6, 0.4, and 0.4, respectively). Additionally, the median value of TSH, BTG, and thyroid uptake showed insignificant differences between the two risk groups (**Table 6**).

**Table 4: clinical and laboratory characteristics in patients with differentiated thyroid cancer according to ATA risk.**

	Low risk	Intermediate risk	P
<b>Age</b>			
• ≤45	86	92	0.1
• >45	42	30	
<b>Sex:</b>			<b>0.007*</b>
• Male	14	29	
• Female	114	93	
<b>Family history</b>			0.4
• Positive	3	5	
• Negative	125	117	
<b>Thyroid scan:</b>			<b>0.02*</b>
• Negative	43	58	
• Positive	85	64	
<b>BTG group:</b>			0.6
• <5 ng/ml	59	62	
• >5 ng/ml	69	60	
<b>Anti Tg:</b>			0.4
• Negative	97	84	
• Positive	27	33	
• Border line	4	5	
<b>Baseline neck US:</b>			0.3
• Free			
• Residual ± LNs	62	52	
	66	70	

**Table 5: Pathological characteristics and RAIT in patients with differentiated thyroid cancer according to ATA risk.**

	Low risk	Intermediate risk	P value
<b>Surgery:</b>			
• Total thyroidectomy	92	43	<b>&lt; 0.01*</b>
• Total thyroidectomy +LN dissection	36	79	
<b>Pathology:</b>			
• Papillary	121	116	0.7
• Follicular	7	6	
<b>N-stage:</b>			
• Nx	92	43	<b>&lt; 0.01*</b>
• N0	34	14	
• N1	2	65	
<b>Thyroid capsule infiltration:</b>			
• Not reported			<b>&lt; 0.01*</b>
• Present	9	13	
• Absent	24	55	
	95	<b>54</b>	
<b>Focality:</b>			
• Uni focal	90	44	<b>&lt; 0.01*</b>
• Multifocal	34	69	
• Not reported	4	9	
<b>Lympho vascular invasion:</b>			
• Absent			<b>&lt; 0.01*</b>
• Present	128	72	
	0	50	
<b>Time interval from surgery to the initial RAI dose:</b>			
• <3 month			0.4
• >3 month	110	101	
	18	21	
<b>Dose of I-131:</b>			
• Low	60	25	<b>&lt; 0.01*</b>
• High	68	97	

Table 6: Descriptive analysis of postoperative baseline TSH, TG, Tc-99m uptake, and RAI dose:

	Total study population		Low risk	Intermediate risk	P-value
	Mean $\pm$ SD	Range	Mean $\pm$ SD	Mean $\pm$ SD	
<b>TSH</b>	82 $\pm$ 40.1	(3-253)	79.8 $\pm$ 41.2	86.2 $\pm$ 38.8	0.1
<b>Baseline TG</b>	17.1 $\pm$ 33.35	(0.02-238.30)	14.3 $\pm$ 25.8	20.1 $\pm$ 39.7	0.8
<b>Thyroid uptake</b>	0.31 $\pm$ 0.52	(0-3.4)	0.3 $\pm$ 0.5	0.3 $\pm$ 0.5	0.06
<b>First RAI dose</b>	87.9 $\pm$ 51.1	(30-175)	72.0 $\pm$ 48.3	104.6 $\pm$ 48.8	< <b>0.01*</b>

According to age, patients under 45 had a successful ablation rate of 64 % in the low-risk patients compared to 57.6 % in the intermediate-risk group. For those over 45, the successful ablation rates were 59.5 % and 63.3 % for the low and intermediate groups, respectively (P:0.6 and 0.5). The female gender represents 114/128 and 93/122 of low- and intermediate-risk patients, respectively, yet the ablation outcome was insignificantly different

between gender types (P: 0.8 and 0.1, respectively).

Three cases with low risk have a positive family history of thyroid cancer compared to 5 cases in the intermediate risk group with insignificant differences in the ablation rate (P:0.8 and 0.07, respectively). 85/128 low-risk patients have positive residual at the thyroid scan with a significantly lower successful ablation rate than those with negative thyroid scans

(55.3 % vs. 76.7 %, P:0.01), this is also applicable to median thyroid uptake (0.1 Vs. 0.2, with p:0.03). On the other hand, no significant difference was observed regarding the intermediate-risk group (p:0.3).

According to BTG subgroups, no significant differences were found in the ablation outcome among low-risk patients (64.4 % vs 60.8 %, P:0.6), while in the intermediate group the ablation outcome in group I was significantly higher than group II (67.7 % vs 50 %, P:0.04). In addition, the median BTG value in low-risk patients with successful ablation outcomes was insignificantly lower than in patients with unsuccessful outcomes (4.8 versus 7.1 ng/ml, respectively, with P: 0.1); the same was true for the intermediate-risk group (3.6 vs. 9.1 ng/ml, respectively with p:0.06). Concerning TG-Abs status, no significant differences were found in the ablation outcome either for low- or intermediate-risk groups (in low-risk patients; successful ablation rates were 59.8 % and 70 % for patients with negative and positive TG-Abs, respectively while in intermediate-risk group the rates were 60.7 % and 57.6 % for

patients with negative and positive TG-Abs, respectively (p:0.5 and p:0.6, respectively). Again, we found no significant differences in the ablation outcome for both risk groups between patients with free N-US and those with residual/LN (successful ablation rates were 61.3 % vs 63.6 %, p:0.7 in the low-risk and 63.5 % vs 55.7 % in the intermediate-risk group, p:0.3, respectively).

The type of surgery and the pathologic variant have no significant difference in the ablation outcome either in the low or intermediate-risk groups (p: 0.5 and 0.6 for low-risk, 0.8 and 0.6 for intermediate-risk, respectively). Among the low-risk group, the successful outcome was higher in patients with the N0-stage than those with the N1-stage, yet no statistical significance was found (67.6 % and 50 %, p:0.7). Still, among the intermediate risk group, there was no significant difference (57.1 % and 58.5, with P: 0.9).

In patients with low risk and absent thyroid capsule infiltration, the successful ablation rate was significantly higher than those with positive thyroid capsule infiltration

(66.6 % vs 62.5 %,  $p:0.03$ ); this is not valid for the intermediate risk group ( $p:0.7$ ). The uni focal tumor had an insignificantly higher successful ablation rate than the multifocal one regardless of the patient's risk (65.6 % vs. 58.8 %,  $P:0.2$  for low-risk groups, and 61.4 % vs. 58 %,  $P:0.9$  for the intermediate risk).

All low-risk patients have no evidence of LVI, with the successful ablation rate being 62.5 %. In the intermediate-risk patients, the successful ablation rate was insignificantly higher in patients without LVI than those with positive LVI ( $p:0.1$ ). 110/128 low-risk patients and 101/122 intermediate patients received their first RAIT within three months of thyroidectomy with successful ablation rates of 60.9 % ( $P:0.3$ ) and 55.4 % ( $P:0.07$ ), respectively. Comparatively, 68/128 low-risk and 97/122 intermediate-

risk patients received a high dose of RAI with a successful outcome rate of 58.8 % and 59.8 %, respectively, with no statistical significance ( $P:0.3$  and 0.7, respectively).

Univariate regression analysis for the low-risk group revealed that absent thyroid capsule infiltration, negative thyroid scan and lower BTG were the significant predictor factors for successful outcome ( $P: 0.02, 0.02$  and  $0.04$ ) (**Table 7**), yet in multivariate regression analysis, negative thyroid scan and lower BTG ( $<5\text{ng/ml}$ ) maintained such significance ( $P: 0.03$  and  $0.04$ , respectively). Univariate regression analysis for the intermediate-risk group revealed that BTG was the only significant predictor factor for successful outcome ( $P:0.02$ ) which maintained significance again in multivariate regression analysis ( $P: 0.007$ ) (**Table 8**).

**Table 7: Regression analysis for the low-risk group.**

Variable	Univariate regression			Multivariate regression		
	B	95 %CI	P-value	B	95 %CI	P-value
Age	0.82	0.38-1.76	0.6	0.796	0.32- 1.95	0.6
Sex	0.91	0.28-2.91	0.8	0.843	0.20- 3.46	0.8
Family history	0.83	0.07-9.40	0.8	0.74	0.05-10.64	0.8
Thyroid scan	0.37	0.16-0.85	<b>0.02*</b>	0.32	0.11-0.90	<b>0.03*</b>
BTG group	0.30	0.09-0.95	<b>0.04*</b>	0.28	0.08-0.99	<b>0.04*</b>
Anti TG	2.0	0.20-20.1	0.5	1.18	0.09-15.41	0.8
Baseline neck US	1.1	0.54-2.26	0.7	1.255	0.52-2.99	0.6
Type of surgery	1.2	0.57-2.88	0.5	0.92	0.34-2.49	0.8
Pathology	1.53	0.28-8.23	0.6	1.10	0.18-6.68	0.9
N-stage	0.59	0.03-9.73	0.7	0.57	0.02-13.04	0.7
Thyroid capsule infiltration	6.8	1.35-35.1	<b>0.02*</b>	1.310	0.44-3.85	0.6
Focality	4.2	0.40-45.5	0.2	0.57	0.22-1.45	0.2
Time interval from surgery to the initial RAI dose	1.66	0.55-5.01	0.3	3.45	.90-13.18	0.07
Dose of I-131	0.71	0.34-1.47	0.3	0.95	.38-2.35	0.9



**Table 8: Regression analysis for the intermediate-risk group.**

Variable	Univariate regression			Multivariate regression		
	B	95 %CI	P-value	B	95 %CI	P-value
Age	1.2	0.54-2.97	0.5	1.390	0.50- 3.80	0.5
Sex	1.7	0.76-4.11	0.1	1.905	0.66- 5.48	0.2
Family history	6.1	0.66-56.98	0.1	8.56	0.58-125.8	0.1
Thyroid scan	0.68	0.33-1.41	0.3	0.88	0.35-2.23	0.7
<b>BTG group</b>	0.30	0.17-0.88	<b>0.02*</b>	0.22	0.08-0.99	<b>0.007*</b>
Anti TG	0.43	0.06-2.72	0.3	1.32	0.14-12.45	0.8
Baseline neck US	0.72	0.34-1.51	0.3	0.75	0.30-1.84	0.5
Type of surgery	0.91	0.42-1.94	0.8	1.03	0.24-4.35	0.9
Pathology	1.4	0.24-8.02	0.6	2.57	0.25 -25.81	0.4
N-stage	0.59	0.46-1.96	0.8	0.81	0.20-3.28	0.7
Thyroid capsule infiltration	0.59	0.16-2.18	0.4	1.23	0.48-3.15	0.6
Focality	1.1	0.272-4.47	0.8	1.06	0.04-2.82	0.8
Lympho- vascular invasion	0.61	0.29-1.27	0.1	0.78	0.33-1.87	0.5
Time interval from surgery to the initial RAI dose	2.57	0.87-7.55	0.08	3.44	0.91-12.93	0.06
Dose of I-131	1.16	0.48-2.83	0.7	2.38	0.69-8.15	0.1

In the low-risk group, ROC analysis found nearly equal AUCs for thyroid uptake and BTG (0.607 Vs. 0.575, p: 0.04 and 0.1, respectively) with a BTG cutoff value 0.2 ng/ml, giving 85 % sensitivity and 83 % specificity in predicting the ablation outcome. In contrast, a cutoff value for the thyroid uptake of 0.2% gives a lower sensitivity and specificity than BTG (65 % and 35 %, respectively). In the

intermediate-risk group, using the same cut off values, ROC analysis again found nearly equal AUCs for BTG and thyroid uptake (0.590 vs 0.541 with P:0.06 and 0.44, respectively) with BTG giving 86 % sensitivity and 87 % specificity. In contrast, while thyroid uptake gives a lower sensitivity (40 %) and specificity (35 %) than BTG (**Figure 3**).




Figure (3) ROC curve analysis of BTG and % thyroid uptake according to the outcome for both risk groups.

## DISCUSSION:

DTC has a good prognosis; however, at the time of diagnosis, it is essential to identify patients who are at a high risk of progressive illness and death from DTC. The best management of DTC, including the extent of thyroid surgery and the rationale for postoperative radioiodine therapy, depends on the identification of

prognostic factors. Treatment plans are customized based on each patient's unique clinico pathological characteristics. Using recognized clinico pathological risk factors, such as advanced age at diagnosis, male sex, lymph node metastasis, and distant metastasis (DM), risk stratification

is used to customize a therapeutic approach for each patient <sup>(11)</sup>.

We observed an overall rate of successful ablation of 60.8% in the current study (62.5 % in the low-risk group compared to 59 % for the intermediate-risk group, P:0.5), which is slightly different from those reported by **Thientunyakit et al.** (49.69%) <sup>(12)</sup> and **Jung et al.**, who stated that 74% of ablations were successful overall; the study population's varied demographics might have brought about this discrepancy (they did not include TG-Abs positive patients) <sup>(13)</sup>. Many studies were done in Egypt about the ablation outcome, with ablation outcome figures in Egyptian patients of 58.9% up to 79.2% <sup>(8, 14, 15)</sup>.

Nearly half the cases (42 patients; 18 low and 24 intermediate-risk cases) with unsuccessful ablation outcomes had indeterminate responses, structurally incomplete response was present in 34 cases (22 low and 12 intermediate-risk patients), a biochemically incomplete response was present in 22 (8 low and 14 intermediate-risk patients). Like our findings, **Li, Hui, et al.** discovered a

greater prevalence of indeterminate responses (71%) in their work; the frequency variation may be related to the study population's various clinical and pathologic features <sup>(16)</sup>.

Age is one of the most critical and reliable risk factors for the ablation outcome of thyroid cancer<sup>(17)</sup>. Our study's findings indicate 86 and 92 cases with low and intermediate-risk respectively aged less than 45 and only 72 (42 low and 20 intermediate-risk) patients aged >45. This outcome is consistent with the study that found the diagnosis was made before age 45. Thyroid cancer is typically found in younger age as a risk factor for ablation outcome <sup>(18)</sup>.

Over the past few decades, thyroid cancer has become more common. This rise in thyroid cancer cases is more likely to worry women than men <sup>(19)</sup>. Thyroid cancer is the only non-reproductive cancer where there is a discernible female preponderance, with a three- to four-fold higher incidence among females, even though males frequently have more aggressive disease <sup>(20)</sup>. We discovered in our cohort that the incidence was higher in

females (81.2% versus 18.8%, respectively) than in males, regardless of the risk group. Given that the male-to-female ratio is 1 to 5, this difference did not significantly affect the disease's ablation outcome (P:0.2). This is consistent with other research that found no relationship between sex and the ablation outcome<sup>(21-23)</sup>.

Several studies reported that patients with negative uptake at the Tc-99m pertechnetate thyroid scan have a higher rate of successful ablation<sup>(12, 24-27)</sup>, this is similar to our results in patients in the low-risk category. Conversely, **Thientunyakit et al.** found no significant association between the percentage of Tc-99m pertechnetate uptake and the final ablation outcome<sup>(12)</sup>; this may be attributed to different sample sizes and demographics.

**Husseini** stated that baseline-stimulated TG level is clinically essential and had a strong predictive value for successful ablation; consequently, increased pre-ablation TG could potentially be incorporated in the decision making for <sup>131</sup>I dosage or other treatment<sup>(6)</sup>. **Lan et al.** concluded that a successful ablation rate is

negatively correlated with the level of BTG; in line with this, we found that the median BTG value in low- and intermediate-risk patients with successful ablation outcomes was insignificantly lower than in patients with unsuccessful outcomes (4.8 versus 7.1 ng/ml, respectively, with P:0.1 in low-risk and 3.6 vs. 9.1 ng/ml, respectively with p:0.06 in intermediate risk). Additionally, we encountered higher successful ablation rates for groups I compared to group II for both risk groups (64.4 % vs 60.8 %, P:0.6 for low risk patients and 67.7 % vs 50 %, P:0.04 for intermediate risk group)<sup>(27)</sup>.

Based on the study populations and the method of serological assays, up to 10% of the general population and  $\geq 20\%$  of patients with DTC have anti-TG in their serum. Several researchers have demonstrated that elevated anti-TG may be a tumor marker for persistent or recurrent DTC<sup>(28)</sup>; however, Gorges et al. did not support this finding<sup>(29)</sup>. The current work found no significant differences in the ablation outcome between patients with low or high levels of anti-TG for either low- or intermediate-risk groups (p:0.5 and 0.6, respectively).

Neck ultrasound is an easy, non-invasive, and highly sensitive method for detecting either abnormal cervical lymph nodes or any thyroid remnant post-thyroidectomy for DTC. It gained a particular emphasis in the American Thyroid Association's guidelines for monitoring DTC patients<sup>(30)</sup>, yet we found no significant difference in the ablation outcome between those with negative or positive neck ultrasound for either low- or intermediate-risk groups (p: 0.7 and 0.3, respectively); this may be attributed to the smaller number of patients who had a free N-US and also by the fact that N-US is an operator dependent.

Like **Lan et al. and Li et al.**, we found no significant effect of multi focality and pathologic type on the disease outcome among both risk groups<sup>(16, 31)</sup>.

Although most of the study population (110/128 low-risk and 101/122 intermediate-risk patients) received their first therapy within three months of thyroidectomy, there were no significant differences in the ablation outcome between those who were ablated within three months and those who received ablation dose more than three months post operatively (P:0.3 and P:0.07, respectively). These results are

different from **Li et al.**, who found that in low- or intermediate-risk DTC patients, delayed initial RAI therapy ( $\geq$  three months after thyroidectomy) was associated with an incomplete response (indeterminate, structural incomplete, or biochemical incomplete response)<sup>(16)</sup>; this may be attributed to different patient demographics.

It is debatable how much radioactive iodine is required to successfully ablate the post-thyroidectomy functioning remnants, with estimates ranging from less than 1110–7400 MBq (30-200 mCi)<sup>(9)</sup>. **Amin et al.** concluded that proper ablation dose of RAIT is a significant predictor for excellent outcome in DTC patients<sup>(8)</sup>. In the present study, 85 patients (60 low-risk and 25 intermediate-risk) received a low dose of RAIT, with a successful ablation rate significantly higher in the low-risk group, 66.7 % versus 56 %, respectively. One hundred sixty-five patients (68 low and 97 intermediate-risk) received a high dose of RAIT, with a successful ablation rate nearly similar in both risk groups, 58.8 % for low and 59.8% for intermediate-risk. These findings agree with **Du et al.**<sup>(32)</sup>, who found no conclusive evidence that 3700 MBq activity is more effective for ablation of the

thyroid remnant than 1110 MBq activity. We evaluate the prognostic factors of independent features on the ablation outcome by univariate regression analysis; the significant predictor factors associated with successful ablation outcome in the low-risk group were absent thyroid capsule infiltration, negative thyroid scan and lower BTG (P: 0.02, 0.02 and 0.04), yet in multivariate regression analysis, negative thyroid scan and lower BTG maintained such significance (P: 0.03 and 0.04, respectively). Univariate regression analysis for the intermediate-risk group revealed that lower BTG was the only significant predictor factor for successful ablation outcome (P:0.02) which maintained significance again in multivariate regression analysis (P: 0.007). This agrees with the results of previous research <sup>(27, 33, 34)</sup>.

**Atilgan et al.** found that serum TG's cutoff value of  $\geq 0.2$ , gives 92.5% had sensitivity

## CONCLUSIONS:

In ATA-low-risk DTC patients, an intact thyroid capsule and a negative post-operative <sup>99m</sup>Tc thyroid scan were linked

and 60% specificity as a predictor of successful ablation outcome (35). We found that the same cutoff value ( $\geq 0.2$ ) gives 85 % sensitivity and 83 % specificity for predicting successful ablation outcome in the low-risk group compared to 86 % sensitivity and 87 % specificity in the intermediate-risk group.

We encountered a cutoff value for the thyroid uptake of 0.2 that gives 65 % sensitivity and 35 % specificity as a predictor of successful ablation outcome in the low-risk group compared to 40 % sensitivity and 35 % specificity in the intermediate-risk group, which are lower than those of **Giovanella et al.**, who found a cutoff value of thyroid uptake of 0.9 %, giving 70%, 55% sensitivity, and specificity respectively<sup>(36)</sup>. This discrepancy may be attributed to the difference in thyroidectomy skills and different surgeons.

to a significantly higher successful ablation outcome. Additionally, a negative thyroid scan and lower BTG ( $<5$  ng/ml)

were the only significant predictor factors for a successful ablation outcome. For the intermediate-risk group, BTG <5 ng/mL was the only significant predictive factor that was significantly linked to a higher successful ablation outcome. Although the percentage of thyroid uptake with a 0.2%

cutoff value and BTG with a cutoff value of 0.2 ng/ml had nearly equal AUCs, BTG has a higher sensitivity and specificity than thyroid uptake in predicting the success of ablation outcomes in DTC patients in both low and intermediate risk categories.

### **Limitations:**

The small sample size, and the retrospective design of the current study were among study limitations.

### **REFERENCES:**

1. **Heydarzadeh S, Moshtaghi AA, Daneshpoor M, et al.** Regulators of glucose uptake in thyroid cancer cell lines. *Cell Communication and Signaling*, 18(1):P.1-16; **2020**.
2. **Wahba HA, El-Hadaad HA, Anter AH, et al.** Impact of Thyroglobulin on Survival and Prognosis of Differentiated Thyroid Cancer. *Journal of Cancer Therapy*, 9(09): P.706; **2018**.
3. **Moini J, Pereira K, Samsam M.** *Epidemiology of Thyroid Disorders*: Elsevier, ISBN 978-0-12-818500-1: P.325; **2020**.
4. **Pryma DA, and Mandel SJ.** Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies. *Journal of Nuclear Medicine*, 55(9):P.1485-91; **2014**.
5. **Schmidbauer B, Menhart K, Hellwig D, et al.** Differentiated thyroid cancer—treatment: state of the art. *International journal of molecular sciences*, 18(6): P.1292; **2017**.
6. **Husseini MA.** Implication of different clinical and pathological variables in patients with differentiated thyroid cancer on successful ablation for 3700 MBq <sup>131</sup>I: a single Egyptian

institutional experience over 14 years. *Annals of nuclear medicine*, 30: P.468-76; **2016**.

7. **Ahmed RA, and Aboelnaga EM.** Thyroid cancer in Egypt: histopathological criteria, correlation with survival and oestrogen receptor protein expression. *Pathology & Oncology Research*, 21: P.793-802; **2015**.

8. **Amin A, Badwey A, El-Fatah S.** Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. *Clinical nuclear medicine*, 39(2): P.142-6; **2014**.

9. **Haugen BR, Alexander EK, Bible KC, et al.** 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*, 26(1): P.1-133; **2016**.

10. **Yao Y, Cheng S, Xu X, et al.** Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer.

*Annals of Translational Medicine*, 8(15); **2020**.

11. **Liu C, Chen T, Zeng W, et al.** Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis. *Scientific reports*, 7(1): P. 11412; **2017**.

12. **Thientunyakit T, Pusuwan P, Tuchinda P, et al.** The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation. *J Med Assoc Thai*, 96(9): P. 1199-207; **2013**.

13. **Jung JS, Lee SM, Kim SJ, et al.** Prediction of the success of thyroid remnant ablation using preablative 99mTc pertechnetate scintigraphy and postablative dual 131I scintigraphy. *Nucl Med Commun*, 36(1):P. 38-44; **2015**.

14. **El-Hadaad HA, Akl MF, Youssef AE-MM, et al.** Assessment of Different Radioactive Iodine Ablation Strategies in Intermediate and High Risk Papillary Thyroid Cancer. *The Egyptian Journal of Hospital Medicine*, 88(1): P. 2653-60; **2022**.

15. **El-rasad S.** Thyroid Remnant Ablation of Differentiated Thyroid



Carcinoma: a comparison of Ablation success with High and Low Doses of Radio-iodine. *Egyptian Journal Nuclear Medicine*, 10(10): P.60-72; **2014**.

16. **Li H, Zhang Yq, Wang C, et al.** Delayed initial radioiodine therapy related to incomplete response in low- to intermediate- risk differentiated thyroid cancer. *Clinical endocrinology*, 88(4): P. 601-6; **2018**;

17. **Shah S, and Boucai L.** Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. *The Journal of Clinical Endocrinology & Metabolism*, 103(2): P. 689-97; **2018**;

18. **Amri A, Soltanian AR, Borzouei S.** Survival rates and prognostic factors of thyroid cancer: A retrospective cohort study. *Journal of Parathyroid Disease*, 10(1); **2022**.

19. **Suteau V, Munier M, Briet C.** Sex Bias in Differentiated Thyroid Cancer. *International Journal of Molecular Sciences*, 22(23): P. 12992; **2021**.

20. **Shobab L, Burman KD, Wartofsky L. et al.** Sex Differences in Differentiated Thyroid Cancer. *Thyroid*. 2022;32(3):224-35.

21. **Yorke E, Melck A, Wiseman SM. et al.** Impact of sex on the clinicopathological characteristics and prognosis of papillary thyroid cancer. *Canadian Journal of Surgery*, 59(4): P. 287; **2016**.

22. **Oyer SL, Smith VA, Lentsch EJ. et al.** Sex is not an independent risk factor for survival in differentiated thyroid cancer. *The Laryngoscope*, 123(11): P. 2913-9; **2013**.

23. **Watanabe K, Uchiyama M, Fukuda K. et al.** The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation. *Japanese Journal of Radiology*, 35: P. 505-10; **2017**.

24. **Tsai C-J, Cheng C-Y, Shen DH-Y, et al.** Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment. *Nuclear medicine communications*, 37(2): P. 182-7; **2016**.

25. **Ozdemir D, Cuhaci FN, Ozdemir E, et al.** The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated

thyroid cancer. Nuclear Medicine Communications, 37(6): P. 640-5; **2016**.

26. **Giovanella L, Suriano S, Ricci R, et al.** Postsurgical thyroid remnant estimation by  $^{99m}\text{Tc}$ -pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck, 33(4):P. 552-6; **2011**.

27. **Lan W, Gege Z, Ningning L, et al.** Negative remnant  $^{99m}\text{Tc}$ -pertechnetate uptake predicts excellent response to radioactive iodine therapy in low-to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy. Annals of Nuclear Medicine, 33: P.112-8; **2019**.

28. **Adil A, Jafri RA, Waqar A, et al.** Frequency and clinical importance of anti-Tg auto-antibodies (ATG). Journal of the College of Physicians and Surgeons--pakistan: JCPSP,13(9): P. 504-6; **2003**.

29. **Gorges R, Maniecki M, Jentzen W, et al.** Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. European Journal of Endocrinology,153(1): P. 49-55; **2005**.

30. **Zaheer S, Tan A, Ang ES, et al.** Post-thyroidectomy neck ultrasonography in patients with thyroid cancer and a review of the literature. Singapore medical journal, 55(4): P.177; **2014**.

31. **Lan W, Gege Z, Ningning L, et al.** Negative remnant  $^{99m}\text{Tc}$ -pertechnetate uptake predicts excellent response to radioactive iodine therapy in low-to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy. Annals of Nuclear Medicine,33(2): P. 112-8; **2019**.

32. **Du P, Jiao X, Zhou Y, et al.** Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials. Endocrine,48: P. 96-105; **2015**.

33. **Puga FM, Al Ghuzlan A, Hartl DM, et al.** Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study. Endocrine, 1: P.10; **2023**.

34. **Rui ZY, Liu Y, Zheng W, et al.** A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clinical and Experimental Medicine, 21: P. 277-86; **2021**.

35. **Atilgan HI, and Yalcin H.** Estimation of Residual Tissue with Thyroid Scintigraphy and Thyroglobulin Level in the Pre-ablative Period of Differentiated Thyroid Carcinoma. The Ulutas Medical Journal, 6(3): P.169-75; **2020.**

36. **Giovanella L, Paone G, Ruberto T, et al.** 99mTc-pertechnetate scintigraphy predicts successful postoperative ablation in differentiated thyroid carcinoma patients treated with low radioiodine activities. Endocrinology and Metabolism,34(1): P. 63-9; **2019.**